Pfizer (United States)-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2017

  1. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children

    Vaccine, Vol. 35, Núm. 35, pp. 4646-4651

2013

  1. Expansion of serotype coverage in the universal pediatric vaccination calendar: Short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain

    Clinical and Vaccine Immunology, Vol. 20, Núm. 10, pp. 1524-1530

  2. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011

    Pediatric Infectious Disease Journal

2011

  1. Clonal and clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: A 2-year (2007-2009) laboratory-based surveillance in Madrid

    Vaccine, Vol. 29, Núm. 9, pp. 1770-1776

  2. Laboratory-based, 2-year surveillance of pediatric parapneumonic pneumococcal empyema following heptavalent pneumococcal conjugate vaccine universal vaccination in madrid

    Pediatric Infectious Disease Journal, Vol. 30, Núm. 6, pp. 471-474

  3. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar

    Clinical and Vaccine Immunology, Vol. 18, Núm. 1, pp. 89-94